ASCO daily highlights: Saturday 1st June
Our team on the ground share 5 key highlights from day 2 at ASCO:
- Genetic testing can provide overwhelming information to recipients, especially patients, and not all of this information is clinically actionable yet. Clearer guidance is needed on reporting genetic test results, specifying which results should be included, so patients can make more informed decisions without confusion.
- Key features, such as linker cleavage enhancing ADC selectivity and new antibody conjugation sites improving stability, have contributed to decreased off-target toxicity and on-target off-tumor toxicity in new ADCs. However, biomarkers that can evaluate ADC toxicity and guide adjustments during early-phase trials to maximize therapeutic benefits and minimize toxicity are still missing.
- Dynamic biomarker testing should be implemented to monitor the efficacy of ADC treatment due to the development of acquired resistance. LBx-based real-time biomarker testing, spatial genomics, and molecular imaging can all contribute to the potential success in ADC treatment.
- Two large population-based studies (one global and one UK biobank study) further solidify the understanding that identifying pathogenic variants early can significantly inform cancer risk reduction and improve clinical outcomes. However, the actual genetic testing rate in practice falls significantly short of guideline recommendations. It is imperative to address this issue to ensure better healthcare outcomes for cancer patients.
- Genomic alterations in ctDNA enhance prognostic accuracy compared to clinical features alone. While evidence supports the prognostic value of ctDNA burden, its predictive value regarding the benefit of LuPSMA treatment requires further clinical validation.
Stay tuned to our for more daily highlights at ASCO!
Schedule a meeting with our team at ASCO using the link below:
https://go.diaceutics.com/ASCO2024
References
Resource: abstract 10512 “Real-world cancer care utilization among patients with breast cancer with germline variants of uncertain significance”; abstract 10513 “Tracking uncertainty in germline genetic testing for hereditary cancer syndromes: Sources, attributes, and resolution of variants of uncertain significance in over 1 million individuals”; abstract 10514 “Gene-environment interactions between clonal hematopoiesis of indeterminate potential and air pollution in non-small cell lung cancer among non-smokers”.
Resource: abstract 3000 “First-in-human trial of M9140, an anti-CEACAM5 antibody drug conjugate (ADC) with exatecan payload, in patients (pts) with metastatic colorectal cancer (mCRC)”; abstract 3001 “First-in-human study of ABBV-706, a seizure-related homolog protein 6 (SEZ6)–targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors”; abstract 3002 “Phase I/II first-in-human study to evaluate the safety and efficacy of tissue factor-ADC MRG004A in patients with solid tumors”.
Resource:educational session “Unlocking the Potential: Biomarkers of Response to Antibody–Drug Conjugates”
Resource: abstract 10503 “Clinical behavior of breast cancer in young BRCA carriers and prognostic impact of the timing of genetic testing: Results from an international cohort study”; abstract 10505 “Association between rare pathogenic variants in established cancer risk genes and the diagnosis of single and multiple common cancers: A UK Biobank study”
Resource: abstract 5007 “A clinical-genetic (CG) circulating tumor DNA (ctDNA)-based prognostic model for predicting overall survival (OS) in men with metastatic castrate-resistant prostate cancer (mCRPC) treated with potent androgen receptor inhibition (Alliance)”; abstract 5008 “Baseline ctDNAanalyses and associations with outcomes in taxane-naive patients with mCRPCtreated with 177Lu-PSMA-617 versus change of ARPI in PSMAfore”.
